22:42 EST 23rd November 2017 | BioPortfolio

The 5-HT6-receptor is expressed in brain regions involved in cognition, such as the cortex and the hippocampus, and modulates activity of multiple neurotransmitter systems. Lu AE58054 is a selective 5-HT6-receptor antagonist. In pre-clinical models, Lu AE58054 was shown to improve cognition and enhance the effects of the acetylcholinesterase inhibitor donepezil on hippocampal function. A number of early trials have demonstrated that a 5-HT6-receptor antagonist could offer potential benefits in the treatment of disorders such as Alzheimer's diseasei and Lundbeck recently presented the positive results of a 24-week clinical phase II trial with Lu AE58054 as adjunctive therapy in Alzheimer's disease.

For further information:

Quick Search

review and buy Lu-AE58054 market research data and corporate reports here